

Author Index Volume 14 (2014)

The issue number is given in front of the pagination

- Abbott, K.L., see Dolezal, S. (1) 55–62
Abdelmaksoud, M.D.E., see Swellam, M. (6) 409–417
Abols, A., K. Ducena, P. Zayakin, K. Silina, Z. Kalnina, L. Sadvoska, J. Tars, J. Vilmanis, Z. Narbutis, J. Eglitis, V. Pirags and A. Line, Survey of autoantibody responses against tumor-associated antigens in thyroid cancer (5) 361–369
Achimias-Cadariu, P., see Pop, L.-A. (2,3) 93–101
Achimias-Cadariu, P., see Saponaro, C. (2,3) 177–184
Adachi, S., see Yamamoto, S. (4) 203–206
Addati, T., see Caponio, M.A. (2,3) 169–175
Ai, H., see Zhang, Y. (5) 353–359
Air, G.M., see Gulati, S. (1) 43–53
Alacam, H., see Salis, O. (6) 419–426
Albrecht, S., L. Unwin, M. Muniyappa and P.M. Rudd, Glycosylation as a marker for inflammatory arthritis (1) 17–28
Amininia, S., see Eskandari-Nasab, E. (5) 343–351
An, L.-J., see Yu, L.-J. (5) 325–333
Araújo-Bravo, M.J., see Ghanjati, F. (5) 295–302
Arioka, H., see Yamamoto, S. (4) 203–206
Arrieta, O., B. Pineda, S. Muñoz-Hernández, D. Flores, G. Ordóñez, J.R. Borbolla-Escoboza and D. Orta, Molecular detection and prognostic value of epithelial markers mRNA expression in peripheral blood of advanced non-small cell lung cancer patients (4) 215–223
Arsovic, A., see Baskic, D. (6) 401–408
Aryal, R.P., see Ju, T. (1) 63–81
Azab, B., F. Mohammad, N. Shah, S. Vonfrolio, W. Lu, S. Kedia and S.W. Bloom, The value of the pre-treatment neutrophil lymphocyte ratio vs. platelet lymphocyte ratio in predicting the long-term survival in colorectal cancer (5) 303–312
Azzariti, A., see Silvestris, N. (2,3) 151–162
Azzoli, C.G., see Lou, E. (4) 207–214
Bahari, G., see Eskandari-Nasab, E. (5) 343–351
Bai, L., see Liao, C. (6) 469–481
Bai, T., see Yu, W. (6) 483–492
Bai, W., see Xu, W. (4) 279–286
Balacescu, L., see Fetica, B. (2,3) 129–135
Balacescu, O., see Fetica, B. (2,3) 129–135
Bankovic, D., see Baskic, D. (6) 401–408
Bao, W., see Xu, X. (5) 381–388
Baskic, D., S. Popovic, D. Bankovic, A. Arsovic, V. Vukovic, I. Zelen and P. Djurdjevic, Evaluation of inflammatory biomarkers as helping diagnostic tool in patients with breast cancer (6) 401–408
Bedir, A., see Salis, O. (6) 419–426
Beermann, A., see Ghanjati, F. (5) 295–302
Berindan-Neagoe, I., see Braicu, C. (2,3) 119–127
Berindan-Neagoe, I., see Chiorean, R. (2,3) 185–194
Berindan-Neagoe, I., see Fetica, B. (2,3) 129–135
Berindan-Neagoe, I., see Pop, L.-A. (2,3) 93–101
Berindan-Neagoe, I., see Susman, S. (2,3) 137–144
Bloom, S.W., see Azab, B. (5) 303–312
Borbolla-Escoboza, J.R., see Arrieta, O. (4) 215–223
Borrini, F., see Coget, J. (2,3) 145–150
Boshnak, H., see Swellam, M. (6) 409–417
Braicu, C., I. Berindan-Neagoe, V. Pileczki, R. Cojocneanu-Petric, L.-A. Pop, E. Puscas, E. Mattioli, A. Irimie and R. Buiga, Breast tumor bank: An important resource for developing translational cancer research in Romania (2,3) 119–127
Braicu, C., see Chiorean, R. (2,3) 185–194
Braicu, C., see Pop, L.-A. (2,3) 93–101
Brodowicz, T., see Mader, R.M. (2,3) 87–91
Brunetti, A.E., see Saponaro, C. (2,3) 177–184
Brunetti, A.E., see Silvestris, N. (2,3) 151–162
Buiga, R., see Braicu, C. (2,3) 119–127
Burz, C., see Silvestris, N. (2,3) 151–162
Can, O., Y. Erdemgil, Z.Z. Yildirim, K. Ozduman, M.N. Pamir, A. Sav and A. Ozpinar, Quantification of fibrin degradation products in glioma and meningioma patients (4) 253–258

- Caponio, M.A., T. Addati, O. Popescu, S. Petroni, V. Rubini, M. Centrone, G. Trojano and G. Simone, P16^{INK4a} protein expression in endocervical, endometrial and metastatic adenocarcinomas of extra-uterine origin: Diagnostic and clinical considerations (2,3) 169–175
- Centrone, M., see Caponio, M.A. (2,3) 169–175
- Cernea, V., see Chiorean, R. (2,3) 185–194
- Chang, F., see Yu, W. (6) 483–492
- Chen, B., see Xu, X. (5) 381–388
- Chen, C.-S., see Tang, H. (5) 313–324
- Chen, K., see Wang, F.-J. (4) 225–231
- Chen, X., see Huang, J. (6) 505–514
- Chen, X., see Zou, Y. (5) 371–379
- Chen, X.-Y., see Yu, L.-J. (5) 325–333
- Cheng, J., see Xu, X. (5) 381–388
- Cheng, L., see Zhao, D.-Y. (6) 449–456
- Cheng, Y.-P., see Jia, M. (6) 493–503
- Cheng, Z.-L., see Li, X.-M. (4) 233–240
- Chiorean, R., I. Berindan-Neagoe, C. Braicu, I.S. Florian, D. Leucuta, C. Montefrancesco, D. Crisan and V. Cernea, Quantitative expression of serum biomarkers involved in angiogenesis and inflammation, in patients with glioblastoma multiforme: Correlations with clinical data (2,3) 185–194
- Chishima, T., see Yamamoto, S. (4) 203–206
- Cicero, G., see Silvestris, N. (2,3) 151–162
- Coget, J., F. Borrini, S. Susman and J.-C. Sabourin, Colorectal carcinomas in 2014: The search for powerful prognostic markers is still on the go! (2,3) 145–150
- Cojocneanu-Petric, R., see Braicu, C. (2,3) 119–127
- Cojocneanu-Petric, R., see Pop, L.-A. (2,3) 93–101
- Crisan, D., see Chiorean, R. (2,3) 185–194
- Cummings, R.D., see Gulati, S. (1) 43–53
- Cummings, R.D., see Ju, T. (1) 63–81
- Danza, K., see Pinto, R. (2,3) 103–117
- De Luca, R., see Silvestris, N. (2,3) 151–162
- De Summa, S., see Pinto, R. (2,3) 103–117
- Delcuratolo, S., see Silvestris, N. (2,3) 151–162
- Dell'Endice, T.S., see Saponaro, C. (2,3) 177–184
- Ding, J.-W., see Yu, M. (5) 389–400
- Ding, Y., see Wang, F.-J. (4) 225–231
- Djordjevic, P., see Baskic, D. (6) 401–408
- Dolezal, S., S. Hester, P.S. Kirby, A. Nairn, M. Pierce and K.L. Abbott, Elevated levels of glycosylphosphatidylinositol (GPI) anchored proteins in plasma from human cancers detected by *C. septicum* alpha toxin (1) 55–62
- Dong, D., see Gao, X. (4) 287–294
- Ducena, K., see Abols, A. (5) 361–369
- Ebrahimi, M., see Eskandari-Nasab, E. (5) 343–351
- Eglitis, J., see Abols, A. (5) 361–369
- El Arab, L.R.E., see Swellam, M. (6) 409–417
- Erdemgil, Y., see Can, O. (4) 253–258
- Eskandari-Nasab, E., M. Hashemi, M. Ebrahimi, S. Amininia, G. Bahari, M.-A. Mashhadi and M. Taheri, Evaluation of CCL5 -403 G>A and CCR5 Δ32 gene polymorphisms in patients with breast cancer (5) 343–351
- Fekete, Z., see Susman, S. (2,3) 137–144
- Fetica, B., O. Balacescu, L. Balacescu, M. Rus and I. Berindan-Neagoe, An alternative and sensitive method based on LCM and Q-PCR for HER2 testing in breast cancer (2,3) 129–135
- Fleisher, M., see Lou, E. (4) 207–214
- Flores, D., see Arrieta, O. (4) 215–223
- Florian, I.S., see Chiorean, R. (2,3) 185–194
- Gao, C., see Xu, X. (5) 381–388
- Gao, X., S. Zhang and Z. Zhu, Genetic variation of *ErbB4* confers risk of colorectal cancer in a Chinese Han population (6) 435–439
- Gao, X., S. Zhang, X. Qiao, Y. Yao, L. Wang, D. Dong, X. Ma and T. Wang, Association of cytotoxic T lymphocyte antigen-4 +49A/G polymorphism and cancer risk: An updated meta-analysis (4) 287–294
- Ghanjati, F., A. Beermann, T. Hermanns, C. Poyet, M.J. Araúzo-Bravo, H.-H. Seifert, M. Schmidpeter, W. Goering, R. Sorg, P. Wernet and S. Santourlidis, Unreserved application of epigenetic methods to define differences of DNA methylation between urinary cellular and cell-free DNA (5) 295–302
- Gildersleeve, J.C., see Muthana, S.M. (1) 29–41
- Goering, W., see Ghanjati, F. (5) 295–302
- Gong, J., H. Zhang, S. Xing, C. Li, Z. Ma, G. Jia and W. Hu, High expression levels of CXCL12 and CXCR4 predict recurrence of adamantinomatous craniopharyngiomas in children (4) 241–251
- Gonzalez-Espinoza, R., see Lou, E. (4) 207–214
- Gulati, S., Y. Lasanajak, D.F. Smith, R.D. Cummings and G.M. Air, Glycan array analysis of influenza H1N1 binding and release (1) 43–53
- Gulten, S., see Salis, O. (6) 419–426
- Guo, J.-F., see Wang, F.-J. (4) 225–231
- Guo, W., see Liao, C. (6) 469–481
- Guo, X., see Zhao, W. (4) 197–202

- Harada, F., see Yamamoto, S. (4) 203–206
Hasegawa, N., see Yamamoto, S. (4) 203–206
Hashemi, M., see Eskandari-Nasab, E. (5) 343–351
Hermanns, T., see Ghanjati, F. (5) 295–302
Hester, S., see Dolezal, S. (1) 55–62
Hu, B., see Xu, W. (4) 279–286
Hu, J., see Zhao, W. (4) 197–202
Hu, W., see Gong, J. (4) 241–251
Hu, X., see Zhao, W. (4) 197–202
Hu, Y., see Zou, Y. (5) 371–379
Huang, J., see Ma, X. (4) 267–277
Huang, J., X. Ma, X. Chen, X. Liu, B. Zhang, M. Li, W. Nie, L. Zhang and L. Liu, Microvessel density as a prognostic factor in bladder cancer: A systematic review of literature and meta-analysis (6) 505–514
- Irimie, A., see Braicu, C. (2,3) 119–127
Irimie, A., see Susman, S. (2,3) 137–144
- Jia, G., see Gong, J. (4) 241–251
Jia, M., Z.-J. Wang, J.-Y. Li, S.-L. Yang, H.-Z. Zhao, Y.-P. Cheng, Z.-B. Luo and Y.-M. Tang, The impact of IKZF1 deletion on the prognosis of acute lymphoblastic leukemia: An updated meta-analysis (6) 493–503
- Jiang, L.-F., see Wang, F.-J. (4) 225–231
Jiang, X., see Yu, W. (6) 483–492
Jin, M.-J., see Wang, F.-J. (4) 225–231
Jing, F.-Y., see Wang, F.-J. (4) 225–231
Johnson, M., see Lou, E. (4) 207–214
Ju, T., R.P. Aryal, M.R. Kudelka, Y. Wang and R.D. Cummings, The *Cosmc* connection to the Tn antigen in cancer (1) 63–81
- Kakuta, Y., see Yamamoto, S. (4) 203–206
Kalnina, Z., see Abols, A. (5) 361–369
Kazanjian, K., see Tang, H. (5) 313–324
Ke, Y., see Yi, S.-Y. (6) 427–433
Kedia, S., see Azab, B. (5) 303–312
Kilinc, V., see Salis, O. (6) 419–426
Kirby, P.S., see Dolezal, S. (1) 55–62
Kong, Q.-Y., see Yu, L.-J. (5) 325–333
Kontogeorgos, G., New horizons in diagnosis and management of endocrine tumors (2,3) 163–167
Kourourian, A., see Roudi, R. (6) 457–467
Koyama, N., Adverse cardiovascular events predict survival benefit in non-small lung cancer patients treated with bevacizumab (4) 259–265
Krasnewich, D., Human glycosylation disorders (1) 3–16
Kris, M.G., see Lou, E. (4) 207–214
- Kudelka, M.R., see Ju, T. (1) 63–81
- Lasanajak, Y., see Gulati, S. (1) 43–53
Leucuta, D., see Chiorean, R. (2,3) 185–194
Li, C., see Gong, J. (4) 241–251
Li, C., see Yu, L.-J. (5) 325–333
Li, C., see Zhang, Y. (5) 353–359
Li, H., see Yu, L.-J. (5) 325–333
Li, J.-Y., see Jia, M. (6) 493–503
Li, M., see Huang, J. (6) 505–514
Li, P., see Ma, X. (4) 267–277
Li, P.-W., see Nie, F. (5) 335–342
Li, X.-M., J.-R. Su, S.-P. Yan, Z.-L. Cheng, T.-T. Yang and Q. Zhu, A novel inflammatory regulator TIPE2 inhibits TLR4-mediated development of colon cancer via caspase-8 (4) 233–240
Li, X.-N., see Yi, S.-Y. (6) 427–433
Li, Y., see Liao, C. (6) 469–481
Li, Y., see Yu, L.-J. (5) 325–333
Liao, C., Z. Yu, W. Guo, Q. Liu, Y. Wu, Y. Li and L. Bai, Prognostic value of circulating inflammatory factors in non-small cell lung cancer: A systematic review and meta-analysis (6) 469–481
- Line, A., see Abols, A. (5) 361–369
Liu, J., see Yu, L.-J. (5) 325–333
Liu, L., see Huang, J. (6) 505–514
Liu, L., see Ma, X. (4) 267–277
Liu, L., see Zhang, Y. (5) 353–359
Liu, Q., see Liao, C. (6) 469–481
Liu, X., see Huang, J. (6) 505–514
Liu, X.-Y., see Yu, L.-J. (5) 325–333
Liu, Z.-L., see Yu, L.-J. (5) 325–333
Lorusso, V., see Silvestris, N. (2,3) 151–162
Lou, E., M. Johnson, C. Sima, R. Gonzalez-Espinoza, M. Fleisher, M.G. Kris and C.G. Azzoli, Serum biomarkers for assessing histology and outcomes in patients with metastatic lung cancer (4) 207–214
- Lu, N.-H., see Yu, M. (5) 389–400
Lu, W., see Azab, B. (5) 303–312
Lu, Y., see Zhao, W. (4) 197–202
Luo, Z.-B., see Jia, M. (6) 493–503
Lv, X., see Yu, W. (6) 483–492
- Ma, X., J. Huang, X. Wu, L. Xie, J. Zhang, L. Xue, P. Li and L. Liu, Epidermal growth factor receptor could play a prognostic role to predict the outcome of nasopharyngeal carcinoma: A meta-analysis (4) 267–277
Ma, X., see Gao, X. (4) 287–294
Ma, X., see Huang, J. (6) 505–514

- Ma, Z., see Gong, J. (4) 241–251
- Mader, R.M., T. Brodowicz and C.C. Zielinski, Translating the molecular analysis of cancer biology into therapeutic concepts (2,3) 87–91
- Madjd, Z., see Roudi, R. (6) 457–467
- Malfettone, A., see Saponaro, C. (2,3) 177–184
- Mangia, A., see Saponaro, C. (2,3) 177–184
- Mao, Y.-Y., see Wang, F.-J. (4) 225–231
- Marech, I., see Silvestris, N. (2,3) 151–162
- Mashhadi, M.-A., see Eskandari-Nasab, E. (5) 343–351
- Mattioli, E., see Braicu, C. (2,3) 119–127
- Mehrazma, M., see Roudi, R. (6) 457–467
- Mirshahidi, S., see Tang, H. (5) 313–324
- Mohammad, F., see Azab, B. (5) 303–312
- Molanae, S., see Roudi, R. (6) 457–467
- Montefrancesco, C., see Chiorean, R. (2,3) 185–194
- Muniyappa, M., see Albrecht, S. (1) 17–28
- Muñiz-Hernández, S., see Arrieta, O. (4) 215–223
- Muthana, S.M. and J.C. Gildersleeve, Glycan microarrays: Powerful tools for biomarker discovery (1) 29–41
- Nageeb, A.M., see Swellam, M. (6) 409–417
- Nairn, A., see Dolezal, S. (1) 55–62
- Nan, S., see Xu, W. (4) 279–286
- Narbutis, Z., see Abols, A. (5) 361–369
- Nie, F., S.-Y. Zhao, F.-X. Song and P.-W. Li, Changes of cytoskeleton and cell cycle in LoVo cells via deletion of *rac1* (5) 335–342
- Nie, W., see Huang, J. (6) 505–514
- Numico, G., see Silvestris, N. (2,3) 151–162
- Okuyucu, A., see Salis, O. (6) 419–426
- Ordóñez, G., see Arrieta, O. (4) 215–223
- Orta, D., see Arrieta, O. (4) 215–223
- Ozduman, K., see Can, O. (4) 253–258
- Ozpinar, A., see Can, O. (4) 253–258
- Pamir, M.N., see Can, O. (4) 253–258
- Paradiso, A., see Saponaro, C. (2,3) 177–184
- Petriella, D., see Pinto, R. (2,3) 103–117
- Petroni, S., see Caponio, M.A. (2,3) 169–175
- Pierce, M., see Dolezal, S. (1) 55–62
- Pilato, B., see Susman, S. (2,3) 137–144
- Pileczki, V., see Braicu, C. (2,3) 119–127
- Pileczki, V., see Pop, L.-A. (2,3) 93–101
- Pineda, B., see Arrieta, O. (4) 215–223
- Pinto, R., S. De Summa, D. Petriella, O. Tudoran, K. Danza and S. Tommasi, The value of new high-throughput technologies for diagnosis and prognosis in solid tumors (2,3) 103–117
- Pirags, V., see Abols, A. (5) 361–369
- Pop, L.-A., E. Puscas, V. Pileczki, R. Cojocneanu-Petric, C. Braicu, P. Achimas-Cadariu and I. Berindan-Neagoe, Quality control of Ion Torrent sequencing library (2,3) 93–101
- Pop, L.-A., see Braicu, C. (2,3) 119–127
- Popescu, O., see Caponio, M.A. (2,3) 169–175
- Popovic, S., see Baskic, D. (6) 401–408
- Poyet, C., see Ghanjati, F. (5) 295–302
- Puscas, E., see Braicu, C. (2,3) 119–127
- Puscas, E., see Pop, L.-A. (2,3) 93–101
- Qiao, X., see Gao, X. (4) 287–294
- Roudi, R., Z. Madjd, A. Korourian, M. Mehrazma, S. Molanae, M.N. Sabet and A. Sharifabrizi, Clinical significance of putative cancer stem cell marker CD44 in different histological subtypes of lung cancer (6) 457–467
- Ruan, J., see Yi, S.-Y. (6) 427–433
- Rubini, V., see Caponio, M.A. (2,3) 169–175
- Rudd, P.M., see Albrecht, S. (1) 17–28
- Rus, M., see Fetica, B. (2,3) 129–135
- Sabet, M.N., see Roudi, R. (6) 457–467
- Sabourin, J.-C., see Coget, J. (2,3) 145–150
- Sadovska, L., see Abols, A. (5) 361–369
- Salis, O., A. Bedir, V. Kilinc, H. Alacam, S. Gulten and A. Okuyucu, The anticancer effects of desferrioxamine on human breast adenocarcinoma and hepatocellular carcinoma cells (6) 419–426
- Santourlidis, S., see Ghanjati, F. (5) 295–302
- Saponaro, C., A. Malfettone, T.S. Dell'Endice, A.E. Brunetti, P. Achimas-Cadariu, A. Paradiso and A. Mangia, The prognostic value of the Na⁺/H⁺ exchanger regulatory factor 1 (NHERF1) protein in cancer (2,3) 177–184
- Sav, A., see Can, O. (4) 253–258
- Schmidtpeter, M., see Ghanjati, F. (5) 295–302
- Seifert, H.-H., see Ghanjati, F. (5) 295–302
- Senthil, M., see Tang, H. (5) 313–324
- Sergio, R.-R., Cancer molecular pathobiology in the clinics: Concluding remarks (2,3) 195–196
- Shah, N., see Azab, B. (5) 303–312
- Sharifabrizi, A., see Roudi, R. (6) 457–467
- Shen, E., see Xu, W. (4) 279–286
- Shen, H., see Zhao, D.-Y. (6) 449–456
- Silina, K., see Abols, A. (5) 361–369
- Silvestris, N., I. Marech, A.E. Brunetti, A. Azzariti, G. Numico, G. Cicero, S. Delcuratolo, R. De Luca, C. Burz and V. Lorusso, Predictive factors to targeted treatment in gastrointestinal carcinomas (2,3) 151–162

- Sima, C., see Lou, E. (4) 207–214
- Simone, G., see Caponio, M.A. (2,3) 169–175
- Smith, D.F., see Gulati, S. (1) 43–53
- Soliman, H.A., see Swellam, M. (6) 409–417
- Song, F.-X., see Nie, F. (5) 335–342
- Sorg, R., see Ghanjati, F. (5) 295–302
- Su, J.-R., see Li, X.-M. (4) 233–240
- Sun, X.-J., see Wang, F.-J. (4) 225–231
- Susman, S., C. Tomuleasa, Z. Fekete, B. Pilato, A. Irimie and I. Berindan-Neagoe, The importance of microRNAs in the stroma-breast cancer cell interplay (3) 137–144
- Susman, S., see Coget, J. (2,3) 145–150
- Swellam, M., H.A. Soliman, M.D.E. Abdelmaksoud, A.M. Nageeb, L.R.E. El Arab and H. Boshnak, Clinical implications of proteolytic activity imbalance in breast cancer diagnosis (6) 409–417
- Taheri, M., see Eskandari-Nasab, E. (5) 343–351
- Tang, H., S. Mirshahidi, M. Senthil, K. Kazanjian, C.-S. Chen and K. Zhang, Down-regulation of LXR/RXR activation and negative acute phase response pathways in colon adenocarcinoma revealed by proteomics and bioinformatics analysis (5) 313–324
- Tang, Y.-M., see Jia, M. (6) 493–503
- Tars, J., see Abols, A. (5) 361–369
- Toda, Y., see Yamamoto, S. (4) 203–206
- Tommasi, S., see Pinto, R. (2,3) 103–117
- Tomuleasa, C., see Susman, S. (2,3) 137–144
- Trojano, G., see Caponio, M.A. (2,3) 169–175
- Tudoran, O., see Pinto, R. (2,3) 103–117
- Unwin, L., see Albrecht, S. (1) 17–28
- Vilmanis, J., see Abols, A. (5) 361–369
- Vonfrolio, S., see Azab, B. (5) 303–312
- Vukovic, V., see Baskic, D. (6) 401–408
- Wang, F.-J., Y. Ding, Y.-Y. Mao, F.-Y. Jing, Z.-Y. Zhang, L.-F. Jiang, J.-F. Guo, X.-J. Sun, M.-J. Jin and K. Chen, Associations between hsa-miR-603 polymorphism, lifestyle-related factors, and colorectal cancer risk (4) 225–231
- Wang, J.-M., see Yao, J. (6) 441–447
- Wang, L., see Gao, X. (4) 287–294
- Wang, P., see Zou, Y. (5) 371–379
- Wang, Q., see Yu, M. (5) 389–400
- Wang, T., see Gao, X. (4) 287–294
- Wang, Y., see Ju, T. (1) 63–81
- Wang, Z.-J., see Jia, M. (6) 493–503
- Wang, Z.-L., see Yao, J. (6) 441–447
- Wernet, P., see Ghanjati, F. (5) 295–302
- Wu, M.-L., see Yu, L.-J. (5) 325–333
- Wu, X., see Ma, X. (4) 267–277
- Wu, Y., see Liao, C. (6) 469–481
- Wu, Y.-N., see Yao, J. (6) 441–447
- Xie, C., see Yu, M. (5) 389–400
- Xie, L., see Ma, X. (4) 267–277
- Xing, S., see Gong, J. (4) 241–251
- Xu, W., S. Nan, W. Bai, E. Shen and B. Hu, Caveolin-1 as a biomarker to predict therapeutic effect of low-frequency ultrasound combined with SonoVue on prostate cancer in nude mice model (4) 279–286
- Xu, X., B. Chen, J. Cheng, C. Gao, X. Zhang and W. Bao, The interleukin-10-1082A>G polymorphism and lymphoma risk: A meta-analysis (5) 381–388
- Xue, L., see Ma, X. (4) 267–277
- Yamamoto, S., T. Chishima, S. Adachi, F. Harada, Y. Toda, H. Arioka, N. Hasegawa and Y. Kakuta, Serum p53 antibody in breast cancer (4) 203–206
- Yan, S.-P., see Li, X.-M. (4) 233–240
- Yang, T.-T., see Li, X.-M. (4) 233–240
- Yang, X.-L., see Jia, M. (6) 493–503
- Yang, Z., see Yu, M. (5) 389–400
- Yao, J., J.-M. Wang, Z.-L. Wang and Y.-N. Wu, The Pin1 gene polymorphism and the susceptibility of oral squamous cell carcinoma in East China (6) 441–447
- Yao, Y., see Gao, X. (4) 287–294
- Yi, S.-Y., J. Ruan, L. Zhao, Y. Ke and X.-N. Li, Metronomic gemcitabine targeted tumor vascular microenvironment decrease the population of CD133⁺ cells in hepatocarcinoma xenografts (6) 427–433
- Yildirim, Z.Z., see Can, O. (4) 253–258
- Ying, K., see Zou, Y. (5) 371–379
- Yu, J., see Zhao, D.-Y. (6) 449–456
- Yu, L.-J., Y. Li, C. Li, H. Li, M.-L. Wu, Z.-L. Liu, Q.-Y. Kong, X.-Y. Chen, X.-Y. Liu, L.-J. An and J. Liu, Restoration of S100A4 expression enhances invasive and metastatic potentials of COLO16 cutaneous squamous cancer cells (5) 325–333
- Yu, M., Q. Wang, J.-W. Ding, Z. Yang, C. Xie and N.-H. Lu, Association between Raf kinase inhibitor protein loss and prognosis in cancers of the digestive system: A meta-analysis (5) 389–400
- Yu, W., X. Jiang, T. Bai, X. Lv and F. Chang, Association between +936 C>T gene polymorphism of vascular endothelial growth factor and lung cancer: A meta-analysis (6) 483–492

- Yu, Z., see Liao, C. (6) 469–481
- Zayakin, P., see Abols, A. (5) 361–369
- Zelen, I., see Baskic, D. (6) 401–408
- Zhang, B., see Huang, J. (6) 505–514
- Zhang, B., see Zhao, W. (4) 197–202
- Zhang, H., see Gong, J. (4) 241–251
- Zhang, J., see Ma, X. (4) 267–277
- Zhang, K., see Tang, H. (5) 313–324
- Zhang, L., see Huang, J. (6) 505–514
- Zhang, S., see Gao, X. (4) 287–294
- Zhang, S., see Gao, X. (6) 435–439
- Zhang, X., see Xu, X. (5) 381–388
- Zhang, X., see Zhao, W. (4) 197–202
- Zhang, X., see Zou, Y. (5) 371–379
- Zhang, Y., L. Liu, C. Li and H. Ai, Correlation analysis between the expressions of leptin and its receptor (ObR) and clinicopathology in endometrial cancer (5) 353–359
- Zhang, Z.-Y., see Wang, F.-J. (4) 225–231
- Zhao, D.-Y., L. Cheng, J. Yu and H. Shen, XRCC1 genetic polymorphism Arg339Gln, Arg194Trp, Arg280His and gastric cancer risk: An evidence based decision (6) 449–456
- Zhao, H.-Z., see Jia, M. (6) 493–503
- Zhao, L., see Yi, S.-Y. (6) 427–433
- Zhao, S.-Y., see Nie, F. (5) 335–342
- Zhao, W., B. Zhang, X. Guo, X. Zhang, J. Hu, X. Hu and Y. Lu, Expression of Ki-67, Bax and p73 in patients with hilar cholangiocarcinoma (4) 197–202
- Zhu, Q., see Li, X.-M. (4) 233–240
- Zhu, Z., see Gao, X. (6) 435–439
- Zielinski, C.C., see Mader, R.M. (2,3) 87–91
- Zou, Y., X. Zhang, X. Chen, Y. Hu, K. Ying and P. Wang, Optimization of volatile markers of lung cancer to exclude interferences of non-malignant disease (5) 371–379